| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2001.19.4.1207 |
| P698 | PubMed publication ID | 11181687 |
| P2093 | author name string | J Wong | |
| S T Fan | |||
| R T Poon | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1207-1225 | |
| P577 | publication date | 2001-02-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Clinical implications of circulating angiogenic factors in cancer patients | |
| P478 | volume | 19 |
| Q47787312 | A critical review on ramucirumab in the treatment of advanced urothelial cancer. |
| Q59339787 | A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases |
| Q94362513 | A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA |
| Q34224045 | A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer |
| Q37294597 | A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers |
| Q35377689 | Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin |
| Q38160129 | Angiogenesis and acute myeloid leukemia |
| Q36959804 | Angiogenesis in Liquid Tumors: An In Vitro Assay for Leukemic-Cell-Induced Bone Marrow Angiogenesis. |
| Q73228269 | Angiogenesis in hematology: a field of active research |
| Q35627784 | Angiogenesis in non-small cell lung cancer. A new target for therapy |
| Q35257111 | Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables |
| Q34742116 | Angiogenesis modulation in cancer research: novel clinical approaches |
| Q36226553 | Angiogenic, lymphangiogenic and adipogenic effects of HIV-1 matrix protein p17. |
| Q36330281 | Anti-VEGF therapies in the clinic |
| Q35577930 | Antiangiogenesis: The Fifth Cancer Treatment Modality? |
| Q37650703 | Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1. |
| Q38786564 | Antitumor and biological investigation of doubly cyclometalated ruthenium(II) organometallics derived from benzimidazolyl derivatives. |
| Q37225055 | Assessment of blood flow in hepatocellular carcinoma: correlations of computed tomography perfusion imaging and circulating angiogenic factors |
| Q34990498 | Association between the Functional Polymorphism of Vascular Endothelial Growth Factor Gene and Breast Cancer: A Meta-Analysis |
| Q36216678 | Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6. |
| Q51567138 | Association of the VEGF 936C>T polymorphism with FDG uptake, clinical, histopathological, and metabolic response in patients with adenocarcinomas of the esophagogastric junction. |
| Q34775716 | Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer |
| Q37159495 | Bevacizumab for the treatment of advanced non-small-cell lung cancer |
| Q35798814 | Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies |
| Q34450520 | Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer. |
| Q27026936 | Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis |
| Q33581458 | Bilateral downregulation of Nav1.8 in dorsal root ganglia of rats with bone cancer pain induced by inoculation with Walker 256 breast tumor cells |
| Q34138326 | Biomarkers for antitumor activity of bevacizumab in gastric cancer models |
| Q37193620 | Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? |
| Q37477466 | Biotherapy in the Adjuvant Treatment of Colorectal Cancer |
| Q38443447 | Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer |
| Q35013211 | Bloodborne biomolecular markers in prostate cancer development and progression |
| Q49335261 | Cancer-associated fibroblasts regulate the biological behavior of cancer cells and stroma in gastric cancer |
| Q37436655 | Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells |
| Q46476659 | Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors |
| Q37198133 | Circulating Natural IgM Antibodies Against Angiogenin in the Peripheral Blood Sera of Patients with Osteosarcoma as Candidate Biomarkers and Reporters of Tumorigenesis |
| Q33683918 | Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab. |
| Q73331954 | Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology |
| Q53489767 | Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma. |
| Q73739890 | Circulating numbers of endothelial progenitor cells in patients with gastric and breast cancer |
| Q35609315 | Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia |
| Q39357711 | Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent |
| Q37484592 | Clinical Implications of VEGF, TGF-β1, and IL-1β in Patients with Advanced Non-small Cell Lung Cancer |
| Q34608643 | Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers |
| Q36012979 | Clinical implications of angiogenesis in cancers |
| Q33633431 | Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials |
| Q35165648 | Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches |
| Q36066175 | Clinical significance of serum vascular cell adhesion molecule-1 levels in patients with hepatocellular carcinoma |
| Q33331462 | Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer |
| Q39768300 | Correlation between angiogenic/inflammatory mediators in Wister rat model of liver dysplasia |
| Q81004411 | Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels |
| Q40178858 | Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration |
| Q39965992 | Design, synthesis, and antitumor activities of some novel substituted 1,2,3-benzotriazines. |
| Q34268230 | Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment |
| Q92311079 | Discovery of 6-Arylurea-2-arylbenzoxazole and 6-Arylurea-2-arylbenzimidazole Derivatives as Angiogenesis Inhibitors: Design, Synthesis and in vitro Biological Evaluation |
| Q33636113 | Discovery of a New Series of Naphthamides as Potent VEGFR-2 Kinase Inhibitors |
| Q35791487 | Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis |
| Q55398386 | Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review. |
| Q53660624 | Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. |
| Q44454015 | Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma |
| Q46374577 | Endocrine effects of erythropoietin in cancer patients |
| Q91904704 | Endothelial Microparticles and Vascular Endothelial Growth Factor in Patients With Head and Neck Cancer Undergoing Radiotherapy or Radiochemotherapy |
| Q52576035 | Evaluation of Detection Methods and Values of Circulating Vascular Endothelial Growth Factor in Lung Cancer. |
| Q47229175 | Evaluation of Endoglin (CD105) expression in pediatric rhabdomyosarcoma. |
| Q36113238 | Exogenous estrogen protects mice from the consequences of obesity and alcohol |
| Q52725090 | Expression and clinical significance of serum MMP-7 and PTEN levels in patients with acute myeloid leukemia. |
| Q33951007 | Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer |
| Q57758506 | Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma |
| Q82087501 | Expression of b-FGF and endostatin and their clinical significance in human osteosarcoma |
| Q36644593 | Expression of basic fibroblast growth factor is associated with poor outcome in non-Hodgkin's lymphoma |
| Q36502150 | Expression of vascular endothelial growth factor in Ewing's sarcoma |
| Q37346563 | FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer |
| Q29616827 | Fibroblast growth factor signalling: from development to cancer |
| Q64906451 | Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome. |
| Q54445032 | Genetic variability of vascular endothelial growth factor and prognosis of head and neck cancer in a Brazilian population. |
| Q27007505 | Genotypic characteristics of resistant tumors to pre-operative ionizing radiation in rectal cancer |
| Q60920093 | Hepatitis C virus core protein modulates several signaling pathways involved in hepatocellular carcinoma |
| Q58552593 | High FNDC1 expression correlates with poor prognosis in gastric cancer |
| Q28344471 | Hypoxia and VEGF mRNA expression in human tumors |
| Q36803674 | Hypoxia markers in human osteosarcoma: an exploratory study. |
| Q39390836 | Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array |
| Q36089956 | Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients. |
| Q39165919 | Immunogenicity and efficacy of a rationally designed vaccine against vascular endothelial growth factor in mouse solid tumor models |
| Q79886534 | Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma |
| Q37451272 | Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474). |
| Q34030193 | In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors |
| Q94586252 | Increased circulating vascular endothelial growth factor in acute myeloid leukemia patients: a systematic review and meta-analysis |
| Q53490169 | Increased vascular endothelial growth factor transcription in residual hepatocellular carcinoma after open versus laparoscopic hepatectomy in a small animal model. |
| Q37498587 | Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function |
| Q47873368 | Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma |
| Q34524915 | MYC in breast tumor progression |
| Q80528721 | Major abdominal surgery increases plasma levels of vascular endothelial growth factor: open more so than minimally invasive methods |
| Q26752752 | Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next? |
| Q36723412 | Markers of angiogenesis and clinical features in patients with sarcoma |
| Q36216552 | Mechanisms of disease: the impact of antithrombotic therapy in cancer patients |
| Q36508092 | Metronomic dosing of chemotherapy: applications in pediatric oncology |
| Q33958925 | Molecular mechanisms of cancer pain |
| Q34017735 | Molecular refinement of clinical staging in hepatocellular carcinoma patients evaluated for potentially curative therapies |
| Q44644595 | Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy. |
| Q37752435 | New anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near future |
| Q37398286 | Non-patient related variables affecting levels of vascular endothelial growth factor in urine biospecimens |
| Q55053130 | Off-tumor target--beneficial site for antiangiogenic cancer therapy? |
| Q34974991 | PET for in vivo pharmacokinetic and pharmacodynamic measurements |
| Q35648921 | Palm tocotrienols decrease levels of pro-angiogenic markers in human umbilical vein endothelial cells (HUVEC) and murine mammary cancer cells |
| Q34491398 | Peroxiredoxin 1 stimulates endothelial cell expression of VEGF via TLR4 dependent activation of HIF-1α. |
| Q92434457 | Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 tria |
| Q34762260 | Platelets and cancer |
| Q36076565 | Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort study |
| Q81525370 | Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers |
| Q36631855 | Post-collection, pre-measurement variables affecting VEGF levels in urine biospecimens |
| Q38185936 | Potential of new therapies like anti-PD1 in kidney cancer |
| Q46117610 | Power Doppler breast ultrasound: association of vascularization and ER/c-erbB-2 co-expression in invasive breast carcinoma |
| Q89835769 | Predictors of 1-year mortality in patients on prolonged mechanical ventilation after surgery in intensive care unit: a multicenter, retrospective cohort study |
| Q41854903 | Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB. |
| Q63432726 | Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons |
| Q92606253 | Prognostic and Predictive Role of Angiogenic Markers in Non- Small Cell Lung Cancer |
| Q42460536 | Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective study |
| Q44819504 | Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy |
| Q51836775 | Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. |
| Q46178918 | Prognostic significance of vascular endothelial growth factor, basic fibroblastic growth factor, and microvessel density and their relation to cell proliferation in B-cell non-Hodgkin's lymphoma |
| Q36649036 | Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients |
| Q84118992 | Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer |
| Q53664103 | Prognostic value of vascular endothelial growth factor in Stage IB carcinoma of the uterine cervix. |
| Q73204483 | Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer |
| Q60929441 | Protein array profiling of circulating angiogenesis-related factors during bevacizumab containing treatment in metastatic colorectal cancer |
| Q34706663 | Putative role of 67 kDa elastin-laminin receptor in tumor invasion |
| Q40301113 | Radiologic Features and Expression of Vascular Endothelial Growth Factor Stratify Survival Outcomes in Patients with Glioblastoma |
| Q43164376 | Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma |
| Q35810123 | Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature |
| Q36875450 | Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil. |
| Q90347558 | Resistance Mechanisms to Anti-angiogenic Therapies in Cancer |
| Q52579594 | Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway. |
| Q35256189 | Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth |
| Q91688483 | Role of Cancer-Associated Fibroblast in Gastric Cancer Progression and Resistance to Treatments |
| Q89835342 | Role of VEGFs/VEGFR-1 Signaling and its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models |
| Q36341778 | Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study |
| Q51392451 | Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study. |
| Q34762171 | Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours |
| Q60340626 | Serum angiogenin levels predict treatment response in patients with stage IV melanoma |
| Q83221570 | Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole |
| Q60339421 | Serum levels of angiogenic cytokines decrease after radiotherapy in non-Hodgkin lymphomas |
| Q35984687 | Serum tumor markers in pediatric osteosarcoma: a summary review |
| Q44181975 | Serum vascular endothelial growth factor levels in patients with colorectal cancer and its prognostic significance |
| Q46171341 | Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor |
| Q38100162 | Targeted agents in non-small cell lung cancer therapy: What is there on the horizon? |
| Q38155932 | Targeted drugs in combination with radiotherapy for the treatment of solid tumors: current state and future developments |
| Q38053680 | Targeting angiogenesis as a promising modality for the treatment of prostate cancer |
| Q35076316 | Targeting angiogenesis in melanoma: prospects for the future |
| Q30358961 | Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy. |
| Q49544424 | The Dawning of Translational Breast Cancer: From Bench to Bedside |
| Q64245905 | The Functional Implications of Endothelial Gap Junctions and Cellular Mechanics in Vascular Angiogenesis |
| Q57053754 | The Role of Angiogenesis in Hepatocellular Carcinoma |
| Q44985069 | The activity of thymidine phosphorylase as a new ovarian tumor marker |
| Q39296184 | The anti-angiogenic activities of glycyrrhizic acid in tumor progression |
| Q34207230 | The application of genomic and molecular data in the treatment of chronic cancer pain |
| Q34980526 | The dual role of thymidine phosphorylase in cancer development and chemotherapy |
| Q38540713 | The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. |
| Q34668320 | The prognostic molecular markers in hepatocellular carcinoma |
| Q36248494 | The role of peroxisome proliferator-activated receptors in colorectal cancer |
| Q39337947 | The safety and efficacy of ramucirumab in combination with docetaxel in the treatment of lung cancer |
| Q36409365 | The significance of cyclooxygenase-2 expression in human hepatocellular carcinoma |
| Q35418973 | Therapeutic advances in women's cancers |
| Q36282728 | Treatment approaches for metastatic Ewing's sarcoma: a review of the literature |
| Q35589206 | Tyrosine kinase inhibitors as cancer therapy |
| Q42017640 | Upregulation of serum vascular endothelial growth factor in patients with salivary gland tumor. |
| Q30844029 | Use of proximity ligation to screen for inhibitors of interactions between vascular endothelial growth factor A and its receptors |
| Q34316762 | Usefulness of circulating vascular endothelial growth factor and neutrophil elastase as diagnostic markers of disseminated intravascular coagulation in non-cancer patients |
| Q37951859 | VEGF gene alternative splicing: pro- and anti-angiogenic isoforms in cancer. |
| Q79863777 | Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer |
| Q80479304 | Vascular endothelial growth factor gene 936 C/T polymorphism in breast cancer patients |
| Q61853685 | Vascular endothelial growth factor gene polymorphisms in ovarian cancer |
| Q38266022 | Vascular endothelial growth factor trap-eye and trap technology: Aflibercept from bench to bedside |
| Q34569994 | Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications |
| Q90285921 | Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma |
| Q36146888 | ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity |
| Q82908447 | [Pain and bone metastases] |
| Q39187173 | p53 promotes VEGF expression and angiogenesis in the absence of an intact p21-Rb pathway. |
Search more.